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ABSTRACT
Aim. To evaluate the prognostic efficacy of the 7th edition
tumor–node–metastasis (TNM) classification compared
with the 6th edition in gastric cancer patients.
Methods. A total of 1,503 gastric cancer patients under-
going surgical resection were staged using the 6th and 7th
edition staging systems. Homogeneity, discriminatory
ability, and monotonicity of gradients of the two systems
were compared using linear trend v2, likelihood ratio v2
statistics, and Akaike information criterion (AIC)
calculations.
Results. Significant differences in 5-year survival rates
were observed for the T, N, and M subgroups using the 7th
edition system, except for stage N2 and N3 patients in the
6th edition system. There were no significant differences in
survival between IB and IIA in the 7th edition system.
Patients with stage IV disease due to T4/N3 in the 6th
edition system who were downstaged to stage III in the 7th
edition system had significantly better survival than those
who remained at stage IV. The 7th edition system had
higher linear trend and likelihood ratio v2 scores, and
smaller AIC values compared with those for the 6th edition,
which represented the optimum prognostic stratification.
Conclusions. Our study suggests that the 7th edition sys-
tem performs better than the 6th edition in several aspects.
Gastric cancer is the fourth most common malignant
tumor in the world, with an estimated 1 million new cases
every year.1 More new cases of gastric cancer are diag-
nosed in China each year than in any other country.2
Although current practice includes incorporating chemo-
therapy or radiation into the treatment protocol, surgical
resection may remain the only chance for curing this dis-
ease.3 Complete surgical resection with radical
lymphadenectomy also provides information for accurate
staging, which is very important in prognosis prediction
and further therapy decisions.
The 6th edition American Joint Committee on Cancer
(AJCC)/International Union against Cancer (UICC) tumor–
node–metastasis (TNM) staging system was published in
2002.4 In recent years, many modifications to the 6th edition
UICC TNM system have been proposed. This year, the
UICC published the 7th edition TNM classification of
malignant tumors for gastric cancer.5 In this edition, the T
classification was changed to contain five subdivisions,
namely T1, T2, T3, T4a, and T4b. Furthermore, subdivision
of the N classification based on the number of metastatic
lymph nodes was also changed. Finally, stage IV classifi-
cation was redefined based on the presence of distant
metastases, and the T4N?/TanyN3M0 classification, which
was defined as stage IV in the 6th edition, was eliminated.
In this study, we aim to evaluate the efficacy and pre-
dictive ability of the 7th edition UICC TNM staging system
and to compare the 6th and 7th editions of the UICC TNM
staging system in a cohort of patients who underwent pri-
mary surgical resection for gastric cancer.
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From January 1994 to December 2006, clinicopatho-
logical data from 1,503 cases of gastric cancer patients who
underwent surgical resection at Sun Yat-Sen University
Cancer Center were analyzed retrospectively. Eligibility
criteria were: (1) gastric adenocarcinoma identified by
histopathological examination, (2) application of gastrec-
tomy plus lymphadenectomy (limited or extended), (3)
complete follow-up data, (4) no history of familial malig-
nancy or other synchronous malignancy [such as
gastrointestinal stromal tumor (GIST), esophageal cancer,
colorectal cancer, etc.], (5) no recurrent gastric cancer and
remnant gastric cancer, and (6) no death in the periopera-
tive period. The principles of tumor resection and D2
lymphadenectomy by experienced surgeons were similar in
all radically resected patients.
Follow-Up
Postoperative follow-up included clinical and laboratory
examinations every 3 months for the first 2 years at our
outpatient department, every 6 months from the third to
fifth years, and annually thereafter until at least 5 years
after the operation or until the patient died, whichever
came first. Overall patient survival, defined as time from
operation to death or last follow-up, was used as a measure
of prognosis.
Statistics
All patients were restaged using the 6th and 7th editions
of the UICC TNM staging systems. Median overall sur-
vival (OS) was determined. Survival curves were plotted
using the Kaplan–Meier method, and the log-rank test was
used to determine significance. Factors that were deemed
of potential importance on univariate analysis were inclu-
ded in multivariate analyses. Multivariate analysis of OS
was performed by means of the Cox proportional-hazards
model using the forward logistic regression (LR) stepwise
procedure for variable selection. Also, since we thought
that we needed to directly compare the 7th UICC TNM
staging system with the 6th edition system, the likelihood
ratio v2 test related to the Cox regression model was used
to measure homogeneity. The discriminatory ability and
monotonicity of gradient assessments were measured with
the linear trend v2 test. To assess potential bias in com-
paring prognostic systems with different numbers of stages,
the Akaike information criterion (AIC) within the Cox
proportional-hazard regression model was used. The AIC
statistic was defined by AIC = -2 log maximum
likelihood ? 2 9 number of parameters in the model. A
smaller AIC value indicated a better model for predicting
outcome.6,7 Hazard ratios (HR) and 95% confidence
intervals (95% CI) were generated. All calculations were
performed using SPSS 18.0 software, and a P value of less
than 0.05 was considered significant.
RESULTS
Median follow-up for the entire cohort was 50 months
(range 3–197 months). Mean age of the 1,503 patients was
56.21 (range 21–85) years; 999 were male, and 504 were
female. The overall 5-year survival rate for all patients was
50.6%, and 741 patients were alive when our follow-up
was completed. The total number of lymph nodes harvested
from all patients in this study was 22,244 (14.80 ± 10.12),
of which 6,773 (4.51 ± 6.34) were positive. The incidence
of nodal involvement was 68.1% overall (1,024 of 1,503
patients). One hundred sixty (10.6%) patients were inci-
dentally found to have distant metastases (abdominopelvic
cavity, ovary, liver, or lung) during the operation and were
classified as M1. No patients died during the initial hospital
stay or first month after surgery.
Univariate and Multivariate Survival Analysis
In all 1,503 patients, 14 factors were found to have
statistically significant associations with overall survival on
univariate analysis. They were age, tumor location, tumor
size, histological type, type of gastrectomy, radical resec-
tion, lymphatic/venous invasion, 6th and 7th UICC T stage,
6th and 7th UICC N stage, M stage, number of retrieved
lymph nodes, and chemotherapy (Table 1). All of the
aforementioned 14 variables were included in a multivar-
iate Cox proportional-hazards model to adjust for effects of
covariates. In our study, the T and N classifications in the
6th and 7th edition system were highly correlated. There-
fore, two separate multivariate models, one with 7th and
the other with 6th edition system, were run to avoid
problems with presence of multicollinearity. In that model,
we demonstrated that age, tumor size, histological grade,
lymphatic/venous invasion, T, N, and M stage, and
retrieved lymph nodes remained independent prognostic
factors (Table 2). Tumor location, type of gastrectomy,
radical resection, and chemotherapy—all of which were
significant prognostic factors on univariate analysis—did
not show significant influence on multivariate analysis.
Concerning radical resection, we believe its prognostic
value was overlapped by the M stage, and thus it did not
show significant influence on multivariate analysis. Con-
cerning chemotherapy, although patients in the adjuvant
treatment group showed better 5-year survival rates on
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univariate analysis (P = 0.013), these values did not reach
significance on multivariate analysis. This finding probably
reflects selection bias, because adjuvant therapy was
offered to more advanced-stage patients.
In our database, the survival curves in each T subgroup
in the 7th edition staging system had excellent discrimi-
natory abilities (P = 0.000, 0.003, 0.000, and 0.000,
respectively), which was also observed for subgroups in the
6th edition (P = 0.000, 0.000, and 0.000, respectively). In
the 6th edition staging system, N stage was categorized as
N0 (no regional lymph node metastasis), N1 (metastasis in
1–6 nodes), N2 (metastasis in 7–15 nodes), and N3
(metastasis in 15 or more nodes). By contrast, according to
the 7th edition TNM classification system, N stage was
reclassified as N0 (no regional lymph node metastasis), N1
(metastasis in 1–2 nodes), N2 (metastasis in 3–6 nodes),
and N3 (metastasis in 7 or more nodes). The Kaplan–Meier
plot for the 6th edition showed discriminative survival
curves for N0 versus N1 and N1 versus N2 (P = 0.000 and
0.000, respectively) but not for N2 versus N3 (P = 0.780).
In the 7th edition, the Kaplan–Meier plot showed dis-
criminatory ability among the subgroups of N0 versus N1,
TABLE 1 Univariate survival analysis of clinicopathologic vari-
ables in 1,503 cases of gastric cancer patients








Female 999 (66.5) 50.8
Male 504 (33.5) 50.3
Age (years) 16.808 0.000
B40 186 (12.4) 58.9
41–60 712 (47.4) 52.9
[61 605 (40.3) 45.5
Tumor location 97.823 0.000
Proximal 637 (42.4) 44.4
Middle 206 (13.7) 47.8
Distal 588 (39.1) 62.1
Two-thirds or more 72 (4.8) 20.4
Tumor size (cm) 94.635 0.000
B5.0 701 (46.6) 63.5
[5.0 802 (53.4) 38.6














Type of gastrectomy 74.616 0.000
Proximal subtotal 603 (40.1) 45.2
Distal subtotal 721 (48.0) 59.9
Total 179 (11.9) 31.5
Radical resection 408.405 0.000
Yes 1,285 (85.5) 57.9




No 1,361 (90.6) 54.1
Yes 142 (9.4) 17.6
Depth of invasion (6th
edition)
242.021 0.000
T1 119 (7.9) 96.6
T2 440 (29.3) 68.3
T3 793 (52.8) 39.3
T4 151 (10.0) 23.4
Depth of invasion (7th
edition)
246.457 0.000
T1 119 (7.9) 96.6
T2 176 (11.7) 74.5
T3 264 (17.6) 64.0
TABLE 1 continued







T4a 793 (52.8) 39.3




N0 479 (31.9) 75.3
N1 665 (44.2) 46.1
N2 269 (17.9) 26.5




N0 479 (31.9) 75.3
N1 298 (19.8) 53.6
N2 367 (24.4) 39.9
N3a 269 (17.9) 26.5
N3b 90 (6.0) 24.8
Metastasis 312.744 0.000
M0 1,344 (89.4) 55.9
M1 159 (10.6) 5.6
Retrieved lymph nodes 70.972 0.000
\15 837 (55.7) 40.9
C15 666 (44.3) 63.1
Chemotherapy 6.173 0.013
Yes 620 (41.3) 53.6
No 883 (58.7) 48.5
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N1 versus N2, and N2 versus N3 (P = 0.000, 0.000, and
0.000, respectively) (Fig. 1).
Figure 2 shows the patient distribution and stage-spe-
cific survival rates. In the 6th edition staging system, the
Kaplan–Meier plot showed no overlapping survival curves
among the six subgroups. In the 7th edition, among all
eight substages, there were similar survival curves between
stages IB and IIA (P = 0.261), while the Kaplan–Meier
plot showed good discriminatory ability among other
substages. However, when classified as four major stages,
the Kaplan–Meier plot showed good discriminatory ability
among stages I through IV in both systems.
The performance of the 6th and 7th edition staging
systems as assessed by the linear trend v2, likelihood ratio
v2, and the AIC tests is presented in Table 3. Compared
with the 6th edition system, the 7th edition system had
better homogeneity (higher likelihood ratio v2 score), dis-
criminatory ability, and monotonicity of gradients (higher
TABLE 2 Multivariate survival analysis results
Variables in the equation
Variables B SE Wald P HR 95% CI
7th edition of the AJCC/UICC TNM staging system
Age 0.148 0.058 6.378 0.012 1.159 1.034 1.300
Tumor size 0.433 0.076 32.531 0.000 1.543 1.329 1.790
Histological grade 0.150 0.051 8.651 0.003 1.162 1.051 1.283
Lymphatic/venous invasion 0.909 0.105 75.095 0.000 2.481 2.020 3.047
AJCC/UICC 7th T 59.270 0.000
T1 (reference) 1.000
T2 1.731 0.524 10.893 0.001 5.644 2.020 15.774
T3 1.978 0.516 14.729 0.000 7.231 2.633 19.862
T4a 2.424 0.509 22.708 0.000 11.289 4.166 30.593
T4b 2.661 0.518 26.419 0.000 14.313 5.188 39.486
AJCC/UICC 7th N 115.623 0.000
N0 (reference) 1.000
N1 0.491 0.124 15.659 0.000 1.634 1.281 2.085
N2 0.726 0.116 39.449 0.000 2.068 1.648 2.594
N3 10.271 0.122 108.170 0.000 3.564 2.805 4.528
AJCC/UICC 7th M 0.798 0.100 63.484 0.000 2.220 1.825 2.701
Retrieved lymph nodes -0.826 0.086 91.919 0.000 0.438 0.370 0.518
6th edition of the AJCC/UICC TNM staging system
Age 0.150 0.058 6.617 0.010 1.162 1.036 1.302
Tumor size 0.436 0.076 32.843 0.000 1.546 1.332 1.794
Histological grade 0.157 0.051 9.555 0.002 1.170 1.059 1.293
Lymphatic/venous invasion 0.907 0.105 74.763 0.000 2.478 2.017 3.044
AJCC/UICC 6th T 59.969 0.000
T1 (reference) 1.000
T2 1.849 .512 13.048 0.000 6.354 2.330 17.328
T3 2.400 .509 22.259 0.000 11.025 4.068 29.882
T4 2.626 .518 25.729 0.000 13.818 5.009 38.114
AJCC/UICC 6th N 117.338 0.000
N0 (reference) 1.000
N1 0.634 0.107 35.304 0.000 1.885 1.529 2.323
N2 1.221 0.126 94.533 0.000 3.391 2.651 4.337
N3 1.565 0.178 76.996 0.000 4.783 3.372 6.784
AJCC/UICC 6th M 0.813 0.100 65.517 0.000 2.255 1.852 2.746
Retrieved lymph nodes -0.885 0.092 93.426 0.000 0.413 0.345 0.494
HR hazard ratio, CI confidence interval, T tumor, N node, M metastasis
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linear trend v2 score). Furthermore, the 7th edition system
had a smaller AIC value, representing optimum prognostic
stratification.
To obtain the best classification of substages for prog-
nosis evaluation of gastric cancer in our statistical analysis,
we used stratified analysis to introduce the factor of tumor
size into substages of 92 cases of IB and 150 cases of IIA.
We found that, in both subgroups of tumor size B5 and
[5 cm, substage IB patients had significantly longer sur-
vival than substage IIA patients. In the subgroup of tumor
size B5 cm, the 5-year survival rate of stage IB and IIA
patients was 95.5 and 84.2%, respectively (P = 0.042),
and in the subgroup of tumor size [5 cm, the 5-year sur-
vival rate of stage IB and IIA patients was 73.9 and 56.8%,
respectively (P = 0.043).
In our study, among 331 cases of stage IV disease in the
6th edition system, 160 cases (48.3%) remained in stage IV
while 130 cases (39.3%) were downstaged to IIIC, 40 cases
(12.1%) to IIIB, and 1 case (0.3%) to IIIA in the 7th edition
system. Therefore, we compared the prognosis of patients
who remained in stage IV and those who were downstaged
to stage III. We found that patients downstaged to stage III
had better prognosis than those who remained in stage IV,
with 5-year survival rates of 28.6% and 5.6%, respectively
(P = 0.000). Even when divided into three subgroups
(group 1, stage IIIB: T3N3bM0, T4bN1M0; group 2, stage
IIIC: T4bN2-3bM0, T4a-4bN3bM0; and group 3, stage IV:
T[any]N[any]M1) according to the 7th edition system, the
patients had distinguishable prognoses. Subgroup 1 had a
significantly better overall survival rate than subgroups 2
and 3 (P = 0.039 and 0.000, respectively) (Fig. 3).
DISCUSSION
The TNM classification system attempts to account for
most basic parameters of cancer, and it has utility for
determining extent of disease, providing guidance for
treatment planning, and predicting outcome. The most
substantial major changes for the 7th edition UICC TNM
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FIG. 1 Comparison of survival curves
according to T between the 6th (a) and
7th edition (b), and N classifications
between the 6th (c) and 7th edition (d)
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Firstly, concerning T classification, the T2 stage in the
6th edition system was subdivided into T2 and T3 in the
7th edition system, and directly resulted in two additional
substages in the 7th edition system in addition to the six
substages in the 6th edition system. Although substages IB
and IIA had no significant difference in survival rates, we
suppose that this finding was caused by differences of
composition and the relatively small number of cases in
these two substages. In our database, subgroups T2 and T3
had significantly different survival curves. Therefore, we
believe the indistinguishable survival curves between
substages IB and IIA were caused by the N status in these
two substages. Substage IB was composed of 9 cases of
T1N1M0 and 83 cases of T2N0M0, and substage IIA was
composed of 8 cases of T1N2M0, 42 cases of T2N1M0,
and 100 cases of T3N0M0. However, when we incorpo-
rated tumor size to subclassify stage IB and IIA in the 7th
edition system, the role of tumor size in gastric cancer
patient survival became important. On univariate and Cox
regression multivariate analyses, we determined tumor size
FIG. 2 Comparison of survival
curves according to 6th and 7th
editions. a, b classified as four
major stages in the 6th and 7th
editions, c classified as six
substages in the 6th edition, and
d classified as eight substages in
the 7th edition (P = 0.000,
respectively)
TABLE 3 Comparison of the performance of the 6th and 7th editions of the AJCC/UICC TNM staging system
TNM staging system Figure Subgroups Linear trend v2 Likelihood ratio v2 AIC
6th edition 2A I, II, III, IV 341.715 371.501 10240.957
2C IA, IB, II, IIIA, IIIB, IV 356.194 406.347 10231.377
7th edition 2B I, II, III, IV 348.459 397.968 10201.315
2D IA, IB, IIA, IIB, IIIA, IIIB, IIIC, IV 386.318 451.862 10162.560
AIC Akaike information criterion
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to be an independent prognostic factor. On stratified anal-
ysis, we found that, in both subgroups of tumor size B5 cm
and [5 cm, patients in substage IB had better prognoses
than did those in substage IIA. Park and colleagues found
subclassification of pT2 gastric cancers into pT2a or pT2b
to be necessary to demonstrate their different prognoses
according to the 6th edition system based on 1,118 cases of
gastric cancer.8 Liu et al. found tumor size to be an inde-
pendent prognostic factor for patients with T3 gastric
cancer in the 6th edition system, and the 5-year survival
rates were 29.5 and 42.7% in the large-size (LSG, tumor
[6 cm) and small-size groups (SSG, tumor B6 cm),
respectively (P = 0.045).9
Secondly, the subdivision of N classification based on
the number of metastatic lymph nodes was changed. The
N1 substage in the old system was divided into N1 and N2
in the new system, and N2 and N3 substages were merged
into N3. Nodal status is a singularly important prognostic
factor in gastric cancer. Actually, many studies had dem-
onstrated N stage in the 6th edition system to be not
suitable for prognostic prediction in clinical analysis,
because of the inappropriate cutoffs of that stage. Deng
et al. determined the most appropriate cutoffs of metastatic
lymph nodes to be 0, 1–4, 5–8, and C9 in 308 gastric
cancer cases with curative resection classified by the 6th
edition system.10 In a group of multicenter retrospective
studies in Italy based on 652 resected early gastric cancer
cases classified by the 6th edition system, Roviello et al.
found the 10-year survival rate in early gastric cancer
patients to be 92% for patients with negative nodes, 82%
for patients with 1–3 positive nodes, 73% for 4–6 positive
nodes, and 27% for [6 positive nodes.11 Similarly, using
multivariate analysis including the number of positive
nodes with cutoffs of 0, 1–4, 5–8, and C9, Wu et al.12
reported that the category of positive nodes was the most
important prognostic indicator for 510 gastric cancer
cases. In accordance with Deng et al., N2 and N3 patients
in our study using the 6th edition system (equivalent to
N3a and N3b in the 7th edition) had similar survival.13
The studies mentioned above show that the 6th edition
UICC N stage less accurately reflected patient prognosis.
Therefore, our results indicated that identifying lymph
node metastases and classifying patients as N3a and N3b
are unnecessary.
Thirdly, partial cases of stage IV disease due to T4 or
N3 in the 6th edition system were downstaged to IIIC, IIIB,
and IIIA in the 7th edition system. An et al. reported each
subgroup of stage IV gastric cancer in the 6th edition
system to have different clinical outcomes, and thus
subclassification of stage IV gastric cancer into IVA
(T1-3N3M0), IVB (T4N1-3M0), and IVM (T[any]-
N[any]M1) might be useful for more accurate prediction of
prognosis.14 Ma et al.15 also predicted that subclassification
of stage IV gastric cancer into IVA (T1-2N3M0), IVB
(T3N3M0 and T4N1-2M0), and IVC (T4N3M0, TanyNa-
nyM1) may be helpful to predict the outcome for patients
with stage IV gastric cancer as classified by the 6th edition
system. Additionally, Ahn et al. determined that survival
for pN3 gastric cancer patients after curative gastrectomy
was significantly longer in the pN3/M0 group as compared
with that of the pN3/M1 group, and advanced T stage was a
predictor of poor prognosis for pN3 patients based on 467
cases of gastric cancer patients classified by the 6th edition
system.16 Park et al.17 found survival of patients with
T4N3M0 and M1 stage disease to be significantly shorter
than that of patients with T1-3N3M0 and T4N1-2M0 stage
disease (P = 0.000) in a 422-patient study. They suggested
that subclassification of stage IV gastric cancer into IVa
(T1-3N3M0, T4N1-2M0) and IVb (T4N3M0, T[any]
N[any]M1) may help predict the outcome of patients with
stage IV gastric cancer as classified by the 6th edition
system. In our study, we also demonstrated that patients
with stage IV in the 6th edition system could be divided
into two subgroups. Patients downstaged to stage III in the
7th edition system had significantly better prognosis than
did those who remained in stage IV. Even when we divided
these patients into three substages (stage IIIB, IIIC, and IV)
according to the 7th edition system, the patients still had
distinguishable prognoses. In our database, only one case
was categorized as having stage IIIA disease in the 7th
edition system, so we excluded this patient from the sur-
vival analysis because the number of patients enrolled was
FIG. 3 Comparison of survival curves between patients downstaged
to stage IIIB and IIIC and those remaining in stage IV in the 7th
edition system (P = 0.039 and 0.000, respectively)
1066 W. Wang et al.
too small. This phenomenon may be explained by the fact
that the three subgroups have different biologic behaviors
of relapse or metastasis models, which still merits further
research.
According to the theory mentioned by Ueno and col-
leagues, the criteria for evaluating the performance of the
staging systems were as follows: (1) homogeneity within
subgroups (small differences in survival among patients
within same stage), (2) discriminatory ability between dif-
ferent groups (greater differences in survival among
patients in different stages), and (3) monotonicity of gra-
dients shown in the association between stages and survival
rates (patients with earlier stages have longer survival than
those in later stages).18 In the 6th edition staging system, the
survival rate of the six substages had significant differences,
while in the 7th edition system, the discriminatory ability
between the eight substages appeared more powerful. As
shown above, the new system had better homogeneity,
discriminatory ability, and monotonicity of gradients.
Additionally, the new system had a smaller AIC value,
representing optimum prognostic stratification.
CONCLUSIONS
Although our sample population was from a single-
institution experience and is relatively small compared
with the worldwide gastric cancer collaboration database,
the surgical procedures, pathologic examinations, and
patient follow-up were highly uniform throughout the
entire study period. Strengths of the 7th edition UICC
TNM staging system include redefinition of T classifica-
tion, redescription for N classification based on the number
of positive lymph nodes, and reclassification of stage IV
disease. Based on analysis of 1,503 gastric cancer patients
who underwent primary surgical resection, we provided an
external validation of the new UICC TNM staging system.
Furthermore, we found that several clinicopathological
variables, especially tumor size, were significant prognos-
tic factors in our database worthy of further research.
Overall, the 7th edition UICC TNM staging system is
superior to the 6th edition system in terms of homogeneity,
discriminatory, and monotonicity of gradients.
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